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Abstract 
Prostate cancer is the most common type of non-skin cancer found in men and 
preliminary evidence suggests prostate cancer has atrophic effects on cardiac and left ventricle 
(LV) mass which are associated with reduced endurance exercise capacity in rats. Using a pre-
clinical orthotopic model of prostate cancer, echocardiography was utilized to test the hypothesis 
that exercise training will mitigate prostate cancer induced-cardiac and skeletal muscle atrophy 
and improve LV function versus sedentary tumor-bearing counterparts. Methods: Dunning R-
3327 AT-1 prostate cancer cells were injected orthotopically in male Copenhagen rats aged 
(n=39; ~5 mo. old). Animals were randomized into four groups, exercise-trained tumor-bearing 
(EXTB) or control (EXCON) and sedentary tumor-bearing (SEDTB), or control (SEDCON). 
Exercise training was performed via a rodent treadmill set at 15m/min with a 15o incline for 60 
min/day for ~30 days. Animals underwent echocardiographic evaluation using the parasternal 
short axis view to examine ventricle dimensions pre-cancer or exercise (PRE) and 15 (Post 1) 
and 30 (Post 2) days post cancer cell injection and/or exercise training with tissues collected 
immediately after Post 2. Results:  Cardiac and LV mass of SEDTB animals were significantly 
lower than all groups (p<0.05). Tumor mass was significantly negatively correlated with LV 
mass in EXTB (-0.75, p<0.02) and SEDTB animals (-0.72, p<0.02). EXCON group had 
significantly higher stroke volume Post 2 assessment compared to both sedentary groups 
(p<0.05), but not EXTB animals. Conclusion: The current investigation demonstrates prostate 
cancer independent of anti-cancer treatment significantly reduces cardiac mass, and LV mass as 
well as locomotor muscle masses. However, moderate intensity exercise training can mitigate 
cardiac and skeletal muscle atrophy with prostate cancer. 
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Chapter 1 - Introduction  
  Cancer-related fatigue is one of the most common cancer related symptoms leading to an 
inability to perform activities of daily living, resulting in reduced quality of life in over 50% of 
cancer patients (9, 24). Although mechanisms of fatigue with cancer are multifaceted, they are 
often attributed to the adverse effects of treatment, as fatigue is common in cancer patients both 
during and after treatment(s) (18, 34). Despite up to 40% of cancer patients reporting fatigue at 
the time of diagnosis (24), the effects of cancer solely on fatigue, and potential 
pathophysiological mechanisms, has received relatively scant attention. Given cancer-related 
fatigue can compromise the completion of anti-cancer treatment regimes, it is clinically 
important to understand how cancer, independent of any conventional treatment(s), affects 
known cardiovascular parameters of exercise capacity (e.g., cardiac function). 
 In men, prostate cancer is the most frequently diagnosed non-skin cancer accounting for 
20% of all new non-skin cancer cases in the United States (3). Upon diagnosis of prostate cancer, 
many patients receive pharmacological or surgical androgen deprivation therapy (ADT), which is 
associated with reductions in muscle mass and bone density (19, 57), and increased 
cardiovascular disease (37). All of which can contribute to fatigue and frailty of patients (33). 
Other adjuvant therapies, such as radiation therapy or chemotherapy, also can elicit and/or 
exacerbate cardiovascular dysfunction (16, 45). In the human cancer patient, it is difficult to 
delineate the mechanisms of fatigue from cancer versus adjuvant therapies, in seperatum, as it is 
unethical to withhold treatment to study the independent effects of cancer (11, 56). Thus, pre-
clinical animal models, with and without cancer, are invaluable to investigate the tumor 
microenvironment and underlying mechanisms (32, 61), and cancer-related fatigue independent 
of treatment (15). Recent evidence suggests prostate cancer induces whole heart and left 
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ventricle (LV) atrophy (5) which were associated with reduced endurance exercise capacity in 
rats (15). Therefore, determining whether exercise training may mitigate cancer induced cardiac 
atrophy independent of treatment is important to potentially combat cancer-related fatigue and 
potentially reduce the cardiotoxicity associated with many adjuvant therapies.   
 Habitual exercise can decrease the morbidity and mortality of many diseases (20, 23) and 
is recognized as a fundamental component of cancer patient care programs (7, 22, 41) to 
attenuate complications, such as fatigue or loss of aerobic capacity (6, 46, 57) associated with 
adjuvant therapies.  Despite exercise prescription, the beneficial effects of aerobic exercise 
training on heart function and structure in prostate cancer populations, independent of therapy, 
are limited (2, 6,). Therefore, the purpose of the current set of investigations was to determine 
whether prostate cancer, independent of treatment, impacts left ventricular mechanics and/or 
function, and determine if aerobic exercise training (also referred to as aerobic exercise therapy) 
can prevent heart and skeletal muscle atrophy that has been previously shown across various 
forms of cancer (2, 15, 34). We hypothesized that prostate cancer-induced cardiac atrophy is 
mitigated with exercise training, and that left ventricular function (assessed with 2-D 
echocardiography) will be preserved in the exercise trained tumor-bearing rat compared to its 
sedentary counterpart.  Further, that exercise training will preserve locomotor skeletal muscle 
mass and oxidative capacity, versus sedentary counterparts, in an established pre-clinical model 
of prostate cancer. 
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Chapter 2 - Methods  
  Animals 
The procedures performed in this study were approved by the Kansas State University 
Institutional Animal Care and Use Committee and  complied with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals (National Research Council 
Committee, Washington, D. C., rev. 2011). Male immunocompetent Copenhagen rats (n=39, ~5 
mo. Old; COP/CrCrl: Charles River Wilmington, MA) were used in this study. Animals were 
housed in a temperature-controlled room (23°C) on a 12:12-hr light-dark cycle, with water and 
standard rat chow provided ad libitum.  
  Orthotopic Model of Cancer 
The cell line utilized in this study was the Dunning R-3327 AT-1 strain of rat prostate 
adenocarcinoma cells, characterized by a high growth rate, low metastatic potential, and similar 
growth characteristics as human prostate cancer (26). AT-1 cells were cultured in RPMI-1640 
media (GE Healthcare Life Sciences, Marlborough, MA) containing 10% fetal bovine serum 
(FBS; RMBIO, Missoula, MT), 2 mM L-glutamine (Fisher Scientific, Hampton, NH), 100 mM 
sodium pyruvate (Thermo Fisher Scientific, Waltham, MA), 1% penicillin/streptomycin (Thermo 
Fisher Scientific), and 0.025 mM dexamethasone (Cayman Chemical,  Ann Arbor, MI) and 
incubated at 37˚C with 5% CO2. Once cells reached ~80-90% confluence, a sample of the cells 
were counted via hemocytometer to calculate proper dilution (100,000 cells/ml) of the viable 
cells for a tumor cell stock solution placed in physiological salt solution (PSS). This solution was 
aliquoted such that each 0.1 mL increment contained ~104 AT-1 cells. These methods have been 
used previously to induce orthotopic prostate tumors (21, 32). 
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In tumor-bearing (TB) rats, animals were anesthetized (2-5% isoflurane, O2 balance) and 
a small incision of ~ 1cm or less was made in the abdomen, lateral of the midline. Under aseptic 
conditions, the bladder/prostate complex was exposed, the ventral lobe of the prostate isolated, 
and 104 AT-1 cells were injected using a sterile 26G insulin syringe. To prevent leakage of cells 
to the tissue surrounding the prostate, a sterile cotton tipped applicator was placed alongside the 
needle during removal. Immediately following injection, the abdominal wall was closed with 
sterile 3–0, polyglycolic acid coated suture (DemeTECH, Miami Lakes, FL) and the overlying 
skin/fascia was closed with 3–0 nylon monofilament (DemeTECH, Miami Lakes, FL) and sealed 
with skin adhesive (3M, Vet-Bond). Rats were administered 0.05mg/kg buprenorphine 
(Patterson Veterinary, Boone, IA) and 0.5mg/kg S.C. acepromazine (Patterson Veterinary, 
Boone, IA) for analgesia and sedation, respectively, and isoflurane was withdrawn. Daily 
postoperative monitoring of the animals was performed until animals were placed into sedentary 
or exercise trained groups ~7 days post-injection.  
  Echocardiographic assessment of LV function 
Three transthoracic echocardiographic evaluations were performed with a commercially 
available 2D ultrasound system (Logiq S8; GE Medical Systems, Milwaukee, WI) with an 
18MHz linear transducer (L8-18i) by a trained sonographer. For primary analysis, the first 
evaluation “Pre” exercise training and/or cancer (Pre) was performed the day preceding tumor 
injection, and post cancer cell injection and/or exercise were performed 15 (Post 1) and 32-35 
(Post 2) days after the onset of exercise training. The Post 1 measure reflects the acute cancer 
state (i.e., prior to any palpable tumors) whereas the Post 2 measure reflects an overt cancerous 
state with palpable tumors in all animals. All system settings and parameters used for 
echocardiographic evaluation remained unchanged throughout the experimental protocol for a 
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given animal. Echocardiographic data was collected and stored on a local hard drive and 
analyzed using the manufacturer’s dedicated software for imaging analysis. For measures, rats 
were anesthetized with 5% isoflurane/O2 balance, placed on a heating pad (42 °C) and 
maintained at 2% isoflurane/ O2 balance for the duration of the study to limit anesthesia effects 
on heart function (43, 50). Hair was removed from the sternum using a depilatory agent prior to 
any measurements. Two-dimensional guided M-mode images were obtained from parasternal 
short-axis views of the left (ventricle) LV at the level of the mitral leaflets in line with previous 
studies (14, 42). The following LV dimensions were measured: Left-ventricular end-diastolic 
and end-systolic dimensions (LVEDD, LVESD), and LV posterior wall thicknesses (PWT) at 
end-diastole and end-systole (PWS, PWD). These values were used in the calculation of volume 
using the Teichholz formula (53) specifically; left ventricular diastolic and systolic volumes 
[LVDV, LVSV= (7/2.4+D)*D3), stroke volume (SV; SV= LVDV-LVSV), fractional shortening 
(FS; FS  =  [(LVEDD-LVESD)/LVEDD]  ×  100), and ejection fraction (EF)  (EF; EF=  [(LVDV-
LVSV)/LVDV]  ×  100). Left Ventricle radial strain (deformation) and strain rate (deformation/D 
time) were derived from two-dimensional parasternal short axis using tissue Doppler imaging 
data as previously described (4). Myocardial function was evaluated using FS, EF, peak systolic 
strain, and peak systolic strain rate values with the mean values from a minimum of three cardiac 
cycles were used for analysis during each visit (52). A representative image collected for the 
non-invasive cardiac measures during systole and diastole is shown in Figure 1.  
  Exercise Training 
Rats were randomly assigned to an exercise-trained control (EXCON) (n = 10), sedentary 
control (SEDCON) (n = 10), exercise-trained tumor-bearing (EXTB) (n=10), and sedentary 
tumor-bearing (SEDTB) (n=9) groups. Animal exercise training began by habituation to 
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treadmill exercise, during which each rat walked on a motor-driven treadmill for ~ 5 min/day at 
15 m/min (0° incline) for 3-5 days. After the habituation period, the incline was raised to 15° for 
the duration of the training period while the 15 m/min speed was maintained. During the first 2 
weeks of training, the time of exercise training was increased by 10 min every 3 days, until 60-
min duration was reached by the 3rd week. The EXCON and EXTB rats continued to exercise 5 
days/week for 60 min/day for the remainder of the ~6-week training period. This training 
program was adapted from McCullough et al. (32). to represent a moderate-intensity of exercise 
training, eliciting ~60-70% of maximal aerobic capacity response from the animal of similar age 
and body mass as previously described (35,36) This moderate intensity of exercise was chosen, 
versus a higher intensity of exercise, as the former was well-tolerated by the animals, and there is 
evidence that the latter may enhance tumor metastases, as suggested by Cohen (12). Both 
EXCON and EXTB rats underwent echocardiography and were euthanized a minimum of 24 
hours after the last bout of exercise to avoid potential effects of acute exercise on reported 
measures. After the Post 2 ultrasound imaging, while under anesthesia (5% isoflurane, O2 
balance) rats were euthanized by a thoracotomy followed by removal of the heart. Subsequently, 
the right ventricle was removed from the left ventricle and intraventricular septum, and the 
tumor, prostate (when delineation from tumor was possible), soleus muscle, plantaris muscle, 
gastrocnemius muscle (subdivided into red and white portions) were immediately excised, 
weighed, flash frozen in liquid nitrogen, and stored at -80˚C for future analyses. The right femur 
was removed, cleaned of connective tissue and remnant muscle, weighed and measured before 
being stored at -80˚C. 
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  Citrate Synthase Activity 
To determine training efficacy, the soleus muscle and red portion of the gastrocnemius 
muscle were used for determination of citrate synthase activity. This mitochondrial enzyme is a 
marker of muscle oxidative potential and was analyzed according to the method of Sere (39). In 
brief, 15 µl and 30 µl samples were diluted using 210 µl and 195 µl of tris buffer, respectively. 
In addition, 15 µl of acetyl coenzyme A (Cayman Chemical, Ann Arbor, MI), and 30 µl of 
DTNB (Thermo Fisher Scientific, Waltham, MA) were added to each sample. Samples were 
incubated in a spectrophotometer (accuSkan GO; Fisher Scientific, Hampton, NH) for 5 min at 
30°C before readings. Following incubation, readings were collected with the spectrophotometer 
at 412 nm once per minute for 5 min followed by the addition of 30 µl of oxalacetic acid (Sigma-
Aldrich, St. Louis, MO) to all samples and immediately analyzed again. Citrate synthase enzyme 
activity is reported as µmol/min/g wet weight of sample tissue. 
 
  Data Analysis 
Prism (version 7.4, Graphpad software, INC., La Jolla, CA) data analysis software was 
used for all statistical analyses. Statistical comparisons were made with either one-way repeated 
measure analysis of variance (ANOVA), or two-way repeated-measure ANOVA with Holm-
Sidak post hoc tests used as appropriate to assess statistical differences between groups for all 
measures. Within the two tumor-bearing groups, Pearson correlations and linear regression 
analyses were performed to quantify relationships between tumor mass and select tissues. A 
p<0.05 was set for statistical significance with data reported as mean±SEM.  
.  
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Chapter 3 - Results 
Body mass increased in both sedentary (SEDCON and SEDTB) and exercise-trained 
(EXCON and EXTB) groups across the ~40-day period of experiments, with significant 
differences between control and tumor-bearing groups (p<0.05, Figure 2). However, there were 
no significant differences between EX and SED for controls or tumor-bearing groups (Figure 2). 
Tumor mass was not significantly different between EXTB vs. SEDTB groups (8.6±1.7 and 
6.6±1.3g, respectively). There were no differences in femur lengths across all groups (EXCON= 
39.2± 0.09mm, SEDCON= 39.0± 0.11 mm, EXTB= 39.1± 0.10 mm, SEDTB=39.0± 0.12 mm, 
p>0.3).  
  Echocardiographic Assessment of LV Function 
Left ventricle measures pre to post-exercise intervention and/or cancer were used to 
analyze potential changes in heart function. There were differences found between groups for a 
number of measures of ventricular function over time, with all groups demonstrating similar 
baseline (i.e., Pre) parameters (Table 2). At Post 3, LVDV, LVSV, and SV were significantly 
higher in the EXCON rats compared to both SEDTB and SEDCON (Table 2), but not different 
versus that of the EXTB group (p≤0.08 for all measures). Longitudinal measures in the EXTB 
group demonstrated a trend for an increased LVDV and SV from Pre to Post 2 (Table 2).  There 
were minimal within group changes between Pre and Post 1, with the exception that EXCON 
group demonstrated significant increases in SV (Table 2). From Pre to Post 2, there was a trend 
for a decreased level of LV strain in only the EXCON (75.7% vs. 59.9% p<0.06).  
 
9 
  Cardiac and Skeletal Muscle Mass and Skeletal Muscle Citrate Synthase Activity 
Cardiac and skeletal muscle mass and citrate synthase activity were all examined post 
exercise intervention and/or cancer in all groups. Absolute mass of the heart, LV, gastrocnemius 
muscle, soleus muscle, and plantaris muscle were all significantly greater (p<0.05) in the 
EXCON group versus both TB groups (Table 1). Heart and left ventricle masses were also 
significantly higher in the EXCON compared to the SEDCON animals (Table 2).  Cardiac tissue 
mass was normalized to body mass and femur length (FL, Table 1) to account for possible 
differences in growth between groups (62). When normalized to body mass or FL, significant 
differences were found between groups for the heart and LV (see Figure 4). However, there was 
no significant difference in RV mass normalized to body mass or femur length between groups 
(Table 1). Skeletal muscle tissue mass was also normalized to both body mass and femur length 
with significant differences between EXCON and SEDCON when compared to the SEDTB for 
gastrocnemius, soleus, and plantaris muscles (Table 1). 
 Within the EXTB bearing group, HR mass, LV mass, and body mass were all 
significantly correlated with tumor mass whereas only LV mass was correlated with tumor mass 
in the SEDTB (Figure 5). In the SEDTB group, there were no significant correlations between 
skeletal muscle mass and tumor mass (Figure 6). Contrastingly, in the EXTB group, there were 
significant negative correlations with tumor mass for both gastrocnemius mass and plantaris 
muscle mass, with a trend (p=0.09) in the soleus muscle (Figure 6). 
 Despite smaller absolute masses, prostate cancer did not affect citrate synthase activity of 
the locomotor skeletal muscles measured in the SEDTB versus SEDCON (Table 3). Skeletal 
muscle citrate synthase activity was greater in both exercise-trained groups versus sedentary 
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counterparts, confirming the efficacy of the training program. There were no differences in 
skeletal muscle citrate synthase activity between exercise-trained groups (Table 3).  
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Table 1. Cardiac and muscle mass characteristics 
 Exercise  
Control 
(n=10) 
Sedentary 
Control                      
(n=10) 
Exercise 
Tumor- 
Bearing 
(n=10) 
Sedentary 
Tumor- 
Bearing 
(n=9) 
Absolute Mass (g)     
Heart 0.95±0.01abc 0.81±0.01a 0.79±0.02a 0.64±0.01 
Left Ventricle 0.73±0.02abc 0.62±0.01ab 0.58±0.01a 0.47±0.01 
Right Ventricle 0.22±0.01 0.20±0.02a 0.21±0.01 0.18±0.02 
Gastrocnemius 2.33±0.05ac 2.09±0.09a 1.88±0.07 1.78±0.07 
Soleus 0.16±0.003ac 0.15±0.004a 0.14±0.004a 0.12±0.003 
Plantaris 0.28±0.004ac 0.26±0.01a 0.25±0.01a 0.21±0.01 
Tumor Mass - - 8.6±1.7 6.6±1.3 
Muscle Mass Normalized to 
Body Mass (mg/g) 
    
Heart/Body mass 2.69±0.04ab 2.40±0.05 2.59±0.06a 2.28±0.07 
Left Ventricle/Body mass 2.07±0.05abc 1.82±0.04a 1.87±0.04a 1.65±0.04 
Right Ventricle/Body mass 0.63±0.03 0.58±0.05 0.68±0.03 0.63±0.06 
Gastrocnemius/Body mass 6.7±0.13 6.2±0.28 6.3±0.21 6.3±0.20 
Soleus/Body mass 0.44±0.01 0.43±0.01 0.46±0.01 0.43±0.02 
Plantaris/ Body mass 0.80±0.01e 0.81±0.01a 0.82±0.02a 0.74±0.02 
Tumor/Body mass - - 30.98±5.9 23.62±4.7 
Mass Normalized to Femur 
Length (FL) (mg/mm) 
    
Heart/ FL 24.13±0.35abc 20.96±0.32a 19.69±0.57a 16.63±0.53 
Left Ventricle/ FL 18.56±0.39abc 15.96±0.46ab 14.25±0.29a 12.00±0.28 
Right Ventricle/ FL 5.57±0.28 5.01±0.39 5.44±0.31 4.64±0.46 
Gastrocnemius/ FL 59.69±1.10ac 53.78±2.49a 48.33±1.65 45.68±1.77 
Soleus/ FL 3.92±0.09a 3.81±0.15a 3.56±0.10e 3.12±0.10 
Plantaris/ FL 7.06±0.16a 6.79±0.11a 6.34±0.33a 5.41±0.16 
Abbreviations: FL, Femur Length  
Data are mean±SEM and were compared with Two-way ANOVA.  
a= p<0.05 vs. Sedentary Tumor-Bearing 
b= p<0.05 vs. Sedentary Control 
c= p<0.05 vs. Exercise Tumor-Bearing 
e= p≤0.07 vs. Sedentary Tumor-Bearing 
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Table 2. Echocardiographic measures 
Abbreviations: LVDV, left ventricle diastolic volume; LVSV, Left ventricle systolic volume; SV, Stroke 
volume; FS, fractional shortening; EF, ejection fraction; v/s, velocity or radial shortening per second.  
Data are mean±SEM and were compared with Two-way ANOVA.  
 
a= p<0.05 vs. Sedentary Tumor-Bearing 
b= p<0.05 vs. Sedentary Control 
c= p≤0.10 vs. Exercise Tumor-Bearing 
d= p≤0.10 vs. Sedentary Control 
e= p≤0.10 vs. Sedentary Tumor-Bearing  
f= p<0.05 Pre vs. Post 1 
g= p<0.05 Pre vs. Post 2 
  
Left Ventricle 
Measures 
Exercise  
Control 
(n=10) 
Sedentary  
Control 
(n=10) 
Exercise  
Tumor-Bearing 
(n=10) 
Sedentary 
Tumor-Bearing 
(n=9) 
Pre-Measure     
LVDV (ml) 0.83±0.04 0.85±0.07 0.83±0.03 0.79±0.05 
LVSV(ml) 0.23±0.03 0.19±0.02 0.21±0.02 0.18±0.02 
SV (ml) 0.59±0.02 0.66±0.06 0.61±0.03 0.60±6 
FS (%) 37.4±2.1 41.8±1.5 39.1±1.3 41.2±2.0 
EF (%) 72.5±2.3 77.8±1.7 74.8±1.5 76.9±2.2 
Strain (%) 76.0±12.1 88.1±13.3 74.1±8.1 82±6.8 
Strain Rate (v/s) 10.3±1.7 10.6±1.6 9.1±0.94 9.8±0.79 
Post 1 Measure     
LVDV (ml) 1.00±0.05  0.95±0.06 0.92±0.06 0.84±0.02 
LVSV(ml) 0.25±0.03  0.25±0.03 0.23±0.02 0.26±0.02 
SV (ml) 0.73±0.03 af 0.70±0.03 e 0.68±0.05 0.59±0.01 
FS (%) 40.6±2.2 37.8±1.5 39.2±1.4 35.0±1.2 
EF (%) 76.1±2.2 73.2±1.7 75.0±1.4 69.8±1.5 
Strain (%) 74.4±7.6  70.3±9.1 74.6±6.1 76.±10.3 
Strain Rate (v/s) 8.69±0.89 7.9±1.18 9.5±0.74 7.2±1.0 
Post 2 Measure     
LVDV (ml) 1.11±0.06 abcg 0.85±0.07 0.93±0.05 0.79±0.03 
LVSV(ml) 0.32±0.04 abcg 0.21±0.02 0.24±0.02 0.21±0.02 
SV (ml) 0.78±0.04 abg 0.65±0.05 0.69±0.03 e 0.58±0.03 
FS (%) 35.4±1.3 40.1±1.6 38.5±1.4 38.4±2.5 
EF (%) 70.0±1.2 75.9±1.9 74.1±1.7 73.7±2.5 
Strain (%) 59.9±6.4 d 93.0±6.1 76.5±8.1 76.0±10.3 
Strain Rate (v/s) 7.1±0.7 10.8±0.90 8.8±0.85 10.4±1.4 
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Table 3. Skeletal muscle citrate synthase activity (µmol/min/g) 
 
Mean±SEM and were compared with Two-way ANOVA.   
a= p<0.05 vs. Sedentary Tumor-Bearing 
b= p<0.05 vs. Sedentary Control 
  
 Exercise 
Control 
(n=9) 
Sedentary 
Control                      
(n=9) 
Exercise 
Tumor- 
Bearing 
(n=9) 
Sedentary 
Tumor- 
bearing 
 (n=9) 
Soleus  24.7±1.4ab 15.5±1.5 25.4±1.2ab 16.9±1.9 
Red gastrocnemius  33.8±1.6ab 26.3±1.5 35.9±1.8ab 23.6±1.0 
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Figure 1. Representative echocardiography images 
A representative rat image in both diastole (top) and systole (bottom) are presented. 2D image of 
LV at the level of the papillary muscle. Bottom panel has the analysis of the left ventricle 
dimensions as follows; 1= end-diastolic dimension of left ventricle, 2= end-diastolic posterior 
wall thickness, 3= end-systolic dimension of left ventricle, 4= end-systolic posterior wall 
thickness, 5= time between end-diastole to end-systole. 
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Figure 2. Change in body mass  
Body mass for both exercise and sedentary control groups were significantly higher (# = p<0.05 than both 
tumor bearing-groups, but not between groups. Tumor-bearing groups had no significant differences in 
body mass between groups. Both Control and Tumor-bearing groups had significant increases in mass 
from Pre-Post 2 (* = p<0.05). 
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Figure 3. Left ventricle change in volume 
The increase in diastolic (A), systolic (B), and stroke (C) volumes of the left ventricle from the first 
echocardiography measures to the final measures. The increases in these volumes were significantly 
higher in the exercise control animals compared to both sedentary groups(# = p<0.05 vs Sedentary tumor-
bearing; *= p<0.05 vs Sedentary control, except for left ventricular systolic volume (LVSV). 
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Figure 4. Cardiac data 
The heart (HR), left ventricle (LV), and right ventricle (RV) wear compared between exercise and 
sedentary control (EXCON, SEDCON) and tumor-bearing groups (EXTB, SEDTB) (Two way-ANOVA 
and Holm-Sidak post hoc tests). # = p<0,05 vs. SEDTB; * = p<0.05 vs. EXTB; $ = p<0.05 vs SEDCON.  
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Figure 5. Cardiac Correlations 
Within the tumor-bearing groups (closed circles) tumor mass was significantly negatively correlated with 
heart mass (B), left ventricle mass (D), and body mass (F) in the exercise-tumor-bearing group (EXTB). 
However, within the sedentary group only left ventricle mass significantly negatively correlated with 
tumor mass (C). The sedentary and exercise control groups are presented as open circles representing the 
mean and SEM (n=10) for each group, of which are shown only for comparison purposes, and are not 
factored into the correlation or regression calculations. 
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Figure 6. Muscle Correlations 
Within the tumor bearing groups (closed circles) tumor mass was significantly negatively correlated with 
gastrocnemius mass (B), plantaris mass (F), and a trend for soleus mass (D) in the exercise-trained tumor-
bearing group (EXTB). The Sedentary and Exercise control groups are presented as open circles 
representing the mean and SEM (n=10) for each group, of which are shown only for comparison purposes 
and are not factored into the correlation or regression calculations. 
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Chapter 4 - Discussion 
 Determination of the effects of prostate cancer on cardiac function and mechanics as well 
as skeletal muscle mass and the possible ability of exercise training to mitigate the effects of 
cancer on these parameters is clinically important. The primary finding of the current 
investigation is the significant atrophic effects of prostate cancer on the heart and skeletal 
muscle. Importantly, we show that exercise training can attenuate most of the atrophic effects in 
both heart and locomotor skeletal muscles. This is important as these results show the underlying 
effects of cancer, independent of treatment. Specifically, with prostate cancer  LV mass was 
negatively correlated with prostate tumor mass, in both EXTB and SEDTB animals. However, 
the LV mass loss with cancer was attenuated with moderate intensity exercise training. These 
findings demonstrate the mitigating effects of aerobic exercise, on cancer-related cardiac 
atrophy. Hence, cancer-related cardiac and skeletal muscle atrophy are likely an underlying 
potential cause of fatigue which may be exacerbated by ADT or adjuvant therapies (15, 57). 
  Prostate Cancer and Atrophy 
 The study of prostate cancer in the absence of treatment is clinically important to 
understanding the underlying mechanisms of the disease in patients prior to treatment. Previous 
work has shown cancer induced atrophy and cachexia in pre-clinical animal models (15, 40, 61) 
and humans (8, 34). Although the tumor-bearing animals in the current study were not cachexic 
(5% loss of body mass without signs of edema), there was significant atrophy of the heart, LV, 
and skeletal muscle in the sedentary group with cancer. There are several mechanisms potentially 
responsible for the atrophy observed herein contributing to the differences in mass, many of 
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which are discussed in a recent review (13). For example, Forkhead boxO (FoxO) expression in 
muscle increases with cancer and has been implicated as an important signaling pathway 
involved in cancer-induced skeletal muscle atrophy (28).  Further, a reduction in spontaneous 
physical activity of the SEDTB group could also induce muscle atrophy through disuse. 
Although spontaneous activity was not measured in the current study, there were no differences 
in locomotor muscle oxidative capacity (Table 3), indirectly suggesting gross alterations in 
spontaneous physical activity between sedentary groups was not present (17).  Compared to 
skeletal muscle, much less is known regarding the effect of prostate cancer on cardiac muscle. 
The ubiquitin ligase system is thought to be a primary contributor in skeletal muscle, and 
possibly in cardiac tissue as well.  However, actual mechanisms are speculative with the 
lysosome, calcium dependent and ubiquitin-dependent systems all as potential pathways of 
atrophy (1, 34). Further, two different E3 ligases i.e., atrogin-1/muscle atrophy F-box(MAFbx), 
and muscle ring finger-1 (MuRF-1), (both of which are upregulated via FoxO) are implicated in 
cancer-related cardiac atrophy (1,63). Specifically, in mice with C26 colon cancer both E3 
ligases were up-regulated and contributed to decreases in cardiac wall thickness and myocardium 
protein degradation (55, 63).  
  Aerobic Exercise Training 
Exercise training is known to increase LV mass in health as well as multiple disease states, 
potentially increasing cardiac output (Q) and aerobic capacity and combating cardiovascular 
dysfunction or increasing exercise performance. Hence, the elevated cardiac masses normalized 
to both body weight and FL were expected in the EXCON group after training, consistent with 
previous research (38, 58, 60). These increases in cardiac mass seen in the EXCON group were 
not as prominent in the EXTB animals, which is likely due to the aforementioned mechanisms of 
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cardiac atrophy with cancer. The lower LV mass of the SEDTB group was likely responsible for 
the significantly lower LVDV and SV versus the EXCON, and a similar trend seen versus 
EXTB. Cardiac atrophy previously associated with time to exhaustion (15) could be attributable 
to modifications in the ubiquitin proteasome system. Thus, the mitigation of cardiac atrophy 
observed with exercise herein could be altering the effect of cancer on the ubiquitin proteasome 
system. Further, exercise training has been demonstrated to prevent rises in heart and skeletal 
muscle FoxO levels during doxorubicin treatment (28). Within the heart, exaggerated levels of 
MAFbx and Murph-1 levels were significantly reduced in a model of heart failure following 4 
weeks of exercise training albeit of lesser volume (1). These findings are thought to be due to the 
chronic attenuation of inflammatory markers, such as tumor necrosis factor alpha (TNF-a) and 
interleukin-6 (IL-6). Specifically, TNF-a is contributing to the expression of MAFbx and 
Murph-1 E3 ligases and was significantly correlated with higher levels of both E3 ligases 
mentioned previously (1), with aerobic exercise training having the potential to regulate the 
expression of the E3 ligases mentioned above either directly, or indirectly through mitigation of 
circulating TNF-a (2). In addition, Padrão and colleagues (40) demonstrated that exercise can 
mitigate cardiac cachexia and remodeling in a pre-clinical model of urothelial carcinoma (40) 
with several potential mechanisms by which exercise training may mitigate cancer-induced 
cachexia. 
  Left Ventricular Function in Prostate Cancer and Exercise  
 In contrast to our hypothesis, there were not large changes in many of the non-invasive 
measures of cardiac function and mechanics in the EXTB versus SEDTB groups, despite 
significant differences in heart and LV mass between groups. Echocardiography evaluation of 
LV function has been a valuable tool in both clinical and pre-clinical investigations due to its 
23 
non-invasive nature and ability to track within subject longitudinal changes in both animals, (10, 
14, 31, 42, 51) and humans (25, 48). In the current study, we show that moderate intensity 
exercise training can mitigate prostate cancer induced atrophy of the LV, with exercise training 
resulting in a comparative heart size in the animals with cancer to that of the healthy sedentary 
controls. This is of higher clinical significance as heart and cardiovascular structure and function 
are important factors in determining the type of, and tolerance to, various anticancer therapies 
(1,11,45). If alterations in the heart (specifically LV) manifest with cancer prior to initiating 
treatment, regular physical exercise may improve heart mass, and potentially decrease both 
cardiac events associated with therapy (7, 57), as well as cancer-induced cardiac cachexic related 
deaths (34).  
 Non-invasively measured LVEDV as an indirect indicator of LV size, was only 
significantly increased in the EXCON animals over time, with a trend for an increase in the 
EXTB group (Table 2, Figure 3). This is in contrast to the absolute masses of the heart collected 
post-mortem (Table 1). Given the relative sensitivity of echocardiography it is difficult to 
delineate small difference in the rodent due to rapid heart rate and small chamber dimensions 
leading to a lack of fidelity of spatial and temporal resolution, which may explain, in part, the in 
vivo versus in vitro differences in measures (38). However, possible mechanisms discussed 
herein (E-3 ubiquitin ligases) that could be contributing to cardiac atrophy, should be 
investigated further as manifestation at a molecular level may delineate earlier changes than 
echocardiography can detect.  
  Limitations 
 Several limitations from this study should be addressed. Food consumption was not 
measured and could lead to decreased levels of protein synthesis, and ultimately contribute to the 
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cardiac or skeletal muscles atrophy in the tumor-bearing groups compared to controls (49, 54). 
However, the continued increase in mass (including non-tumor mass of all groups) and that 
femur length was not different between groups suggests growth rates of the cancer group were of 
similar proportion to the control groups indicating normal growth patterns (47). With no 
differences between groups in mean tumor mass, the similar burden of the tumor between EXTB 
and SEDTB groups strengthens the comparisons between groups. This similar tumor-burden 
coupled with the orthotopic model of cancer (vs. ectopic models) also strengthens the 
translational development of this particular cancers effects as the tumor is matched to its host 
tissue (i.e., prostate tumor in prostate) (29), on the heart and skeletal muscles. This is particularly 
important with exercise as the orthotopic model also mitigates possible confounding differences 
versus ectopic models on site-specific tumor blood flow with exercise, as previously shown (21). 
Lastly, the length of time and exercise modality requisite to induce significant increases in 
cardiac structure and function are debated in healthy humans as well as in clinical and pre-
clinical studies (44, 59, 60). From animal studies, the ideal length of training is typically 6-8 
weeks of constant load moderate intensity exercise to induce an exercise phenotype (30). Due to 
the growth rate of these cancer cells, the entire duration of the study could not be extended 
beyond 5-6 weeks due to potential tumor size limitation and ethical treatment of the animals. 
Hence, a longer period of training may have been needed to induce functional and mechanical 
changes in the LV between the ETB and SEDTB groups. 
  Conclusions 
 In summary, this investigation demonstrates that prostate cancer, independent of any 
adjuvant therapy, in a pre-clinical orthotopic prostate tumor model induces atrophy of cardiac, 
and select locomotor skeletal muscles. Furthermore, these reductions in muscle mass were 
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significantly negatively correlated with tumor mass, primarily among the EXTB animals. 
Although there are multiple potential contributing mechanisms to these reductions in muscle 
masses with cancer in tumor-bearing animals, exercise training mitigates gross changes in 
cardiac mass, and may benefit the patient and further support the importance of including 
exercise as a fundamental component of cancer patient care. Information garnered herein provide 
important insights into possible mechanisms of fatigue in cancer patients that could be 
exacerbated by concomitant treatment. Lastly, the present investigation promotes further 
investigation into the mechanisms by which prostate cancer independently reduces cardiac and 
locomotor skeletal muscle mass, and further the role of exercise in the attenuation of 
aforementioned reductions. 
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